4.8 Review

Boolean logic in synthetic biology and biomaterials: Towards living materials in mammalian cell therapeutics

Journal

CLINICAL AND TRANSLATIONAL MEDICINE
Volume 13, Issue 7, Pages -

Publisher

JOHN WILEY & SONS LTD
DOI: 10.1002/ctm2.1244

Keywords

biomaterials; boolean logic; CAR T cells; cell therapy; drug delivery; synthetic biology

Ask authors/readers for more resources

The intersection of synthetic biology and biomaterials holds great promise for improving safety and efficacy in novel therapeutics. Recent research has shown that the use of Boolean logic in these fields can lead to the development of new and effective living therapeutics, such as stimuli-responsive drug delivery devices and logic-gated CAR T cells. Collaborations between synthetic biology and biomaterials have resulted in advancements in drug delivery and cell therapy, with potential benefits including enhanced safety and efficacy.
Background: The intersection of synthetic biology and biomaterials promises to enhance safety and efficacy in novel therapeutics. Both fields increasingly employ Boolean logic, which allows for specific therapeutic outputs (e.g., drug release, peptide synthesis) in response to inputs such as disease markers or bio-orthogonal stimuli. Examples include stimuli-responsive drug delivery devices and logic-gated chimeric antigen receptor (CAR) T cells. In this review, we explore recent manuscripts highlighting the potential of synthetic biology and biomaterials with Boolean logic to create novel and efficacious living therapeutics.Main body: Collaborations in synthetic biology and biomaterials have led to significant advancements in drug delivery and cell therapy. Borrowing from synthetic biology, researchers have created Boolean-responsive biomaterials sensitive to multiple inputs including pH, light, enzymes and more to produce functional outputs such as degradation, gel-sol transition and conformational change. Biomaterials also enhance synthetic biology, particularly CAR T and adoptive T cell therapy, by modulating therapeutic immune cells in vivo. Nanoparticles and hydrogels also enable in situ generation of CAR T cells, which promises to drive down production costs and expand access to these therapies to a larger population. Biomaterials are also used to interface with logic-gated CAR T cell therapies, creating controllable cellular therapies that enhance safety and efficacy. Finally, designer cells acting as living therapeutic factories benefit from biomaterials that improve biocompatibility and stability in vivo.Conclusion: By using Boolean logic in both cellular therapy and drug delivery devices, researchers have achieved better safety and efficacy outcomes. While early projects show incredible promise, coordination between these fields is ongoing and growing. We expect that these collaborations will continue to grow and realize the next generation of living biomaterial therapeutics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available